Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of MEK162 in Combination With Capecitabine in Gemcitabine-pretreated Advanced Biliary Tract Cancer

NCT02773459 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT02773459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02773459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of MEK162 in Combination With Capecitabine in Gemcitabine-pretreated Advanced Biliary Tract Cancer
Lead sponsor
Seoul National University Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2016
Completion date
January 7, 2019
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer